Pharma: The Year 2014 in Images
These are my favorite images and posts that appeared in Pharma Marketing Blog in 2014 (see embedded slide deck below - you can also...
Et Tu, Amgen? Blincyto’s Bling! Bling! Price Tag!
FDA approved Amgen's Blincyto (blinatumomab) on December 3, 2014, as a second-line treatment for Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia, which affects around...
Pfizer’s “Humorous” Menopause Ad Mentions the “V” Word
Pfizer marketers have done it again! First it was an all-female Viagra ad campaign for the treatment of ED (erectile dysfunction; read "Oh Yeah,...
37% of New Drugs Approved by FDA in 2014 were for Treatment of Rare...
New data from the FDA (here) shows that 2014 was a banner year for orphan drugs, which are drugs that treat "rare" diseases/disorders affecting...
Back to the Future of Mobile Health Apps with Professor SYRUM’s Nephew
There is no more cherished and insulting image of a scientist/researcher than the "mad scientist" persona often depicted in cartoons.
A case in point is...
Is IMS Health’s Mobile Health App “Certification” Program Doomed to #FAIL?
"Welcome to the wild, wild, west of mobile health apps," says the voice over of an IMS Health animated Youtube video (embedded at the...
La Maladie du Grand Print Out: A Condition Abetted by Pharma Marketing & “Patient...
"Of course I was familiar, from my own practice, with the phenomenon of patients making lists, but I'd never known it had a name,"...
Galderma and PMCPA Tangle in a Toxic Tussle
Galderma and PMCPA Tangle in a Toxic Tussle
Galderma tried to lay the blame on a rogue Key Account Manager (KAM), but PMCPA would have...
US Internet Users Don’t Need No Stinkin’ Mobile Apps!
Pharmaceutical companies have a lot of apps in the market, and have been making apps for a long time, but their apps aren’t seeing...
Does Your Spouse Influence Your DTC Viewing Experience?: FDA Wants to Peek Into Your...
This article is a review of FDA's proposed study titled 'Spousal Influence on Consumer Understanding of and Response to Direct-To-Consumer Prescription Drug Advertisements' (FDA-2014-N-1819)
